6DW Stock Overview
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
D. Western Therapeutics Institute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.55 |
| 52 Week High | JP¥1.33 |
| 52 Week Low | JP¥0.51 |
| Beta | 0.73 |
| 1 Month Change | -16.03% |
| 3 Month Change | -29.03% |
| 1 Year Change | -56.35% |
| 3 Year Change | -73.81% |
| 5 Year Change | -81.76% |
| Change since IPO | -82.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6DW | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.8% | 1.8% | -1.2% |
| 1Y | -56.3% | -19.8% | 1.8% |
Return vs Industry: 6DW underperformed the German Biotechs industry which returned -19.8% over the past year.
Return vs Market: 6DW underperformed the German Market which returned 1.8% over the past year.
Price Volatility
| 6DW volatility | |
|---|---|
| 6DW Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6DW's share price has been volatile over the past 3 months.
Volatility Over Time: 6DW's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 21 | Yuichi Hidaka | www.dwti.co.jp |
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension.
D. Western Therapeutics Institute, Inc. Fundamentals Summary
| 6DW fundamental statistics | |
|---|---|
| Market cap | €21.51m |
| Earnings (TTM) | -€4.94m |
| Revenue (TTM) | €2.60m |
8.3x
P/S Ratio-4.4x
P/E RatioIs 6DW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6DW income statement (TTM) | |
|---|---|
| Revenue | JP¥428.00m |
| Cost of Revenue | JP¥36.00m |
| Gross Profit | JP¥392.00m |
| Other Expenses | JP¥1.20b |
| Earnings | -JP¥812.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -25.27 |
| Gross Margin | 91.59% |
| Net Profit Margin | -189.72% |
| Debt/Equity Ratio | 69.1% |
How did 6DW perform over the long term?
See historical performance and comparison